Skip to main content
Top

Open Access 03-02-2025 | Kidney Cancer | Original Article

Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy

Authors: Kosuke Ueda, Naoki Ito, Yuya Sakai, Satoshi Ohnishi, Taishi Hirano, Hirofumi Kurose, Katsuaki Chikui, Keiichiro Uemura, Kiyoaki Nishihara, Makoto Nakiri, Shigetaka Suekane, Tsukasa Igawa

Published in: International Journal of Clinical Oncology

Login to get access

Abstract

Background

Immuno-oncology (IO) combination therapies, including IO + IO or IO + vascular endothelial growth factor targeted therapies (VEGF-TT), have become the standard first-line treatment for advanced renal cell carcinoma (RCC). However, the optimal regimen for patients without prior nephrectomy remains unclear.

Methods

Data from 99 patients with advanced RCC without nephrectomy, treated with VEGF-TT, IO + IO, or IO + VEGF-TT between May 2008 and May 2024, were retrospectively reviewed and analyzed. Patients were divided into VEGE-TT, IO + IO, and IO + VEGF-TT groups based on their first-line treatment, and survival and tumor response were compared.

Results

All patients included in this study were categorized as either intermediate or poor risk according to the International Metastatic RCC Database Consortium risk classification. Among the 99 included patients, 41 initiated first-line therapy with VEGF-TT, 36 with IO + IO, and 22 with IO + VEGF-TT. The objective response rates were 17.5% for VEGF-TT, 38.9% for IO + IO, and 61.9% for IO + VEGF-TT. Notably, the IO + VEGF-TT group showed the greatest shrinkage of target kidney lesions (p = 0.0042). In multivariate analyses, bone metastasis (hazard ratio (HR) = 1.812, 95% confidence interval (CI) 1.017–3.228, p = 0.0436) and the first-line regimen (VEGF-TT vs IO + VEGF-TT: HR = 0.129, 95% CI 0.045–0.369, p = 0.0001) were independent prognostic factors for progression-free survival. The first-line regimen (VEGF-TT vs IO + VEGF-TT: HR = 0.303, 95% CI 0.104–0.879, p = 0.0279) independently affected overall survival.

Conclusion

IO combination therapy, especially IO + VEGF-TT, has demonstrated a higher anti-tumor response in patients with advanced RCC without nephrectomy and may also be highly effective against primary renal tumors. Therefore, further studies are needed to improve patient survival and validate efficacy of IO combination therapy.
Literature
1.
go back to reference Ueda K, Suekane S, Kurose H et al (2022) Improved survival of real-world Japanese patients with advanced renal cell carcinoma treated with immuno-oncology combination therapy. Anticancer Res 42:4573–4580CrossRefPubMed Ueda K, Suekane S, Kurose H et al (2022) Improved survival of real-world Japanese patients with advanced renal cell carcinoma treated with immuno-oncology combination therapy. Anticancer Res 42:4573–4580CrossRefPubMed
2.
go back to reference Fiala O, Buti S, Bamias A et al (2024) Real-world impact of upfront cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma treated with first-line immunotherapy combinations or tyrosine kinase inhibitors (A sub-analysis from the ARON-1 retrospective study). Target Oncol 19:587–599CrossRefPubMedPubMedCentral Fiala O, Buti S, Bamias A et al (2024) Real-world impact of upfront cytoreductive nephrectomy in metastatic non-clear cell renal cell carcinoma treated with first-line immunotherapy combinations or tyrosine kinase inhibitors (A sub-analysis from the ARON-1 retrospective study). Target Oncol 19:587–599CrossRefPubMedPubMedCentral
3.
go back to reference Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427CrossRefPubMed Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 379:417–427CrossRefPubMed
4.
go back to reference Bex A, Mulders P, Jewett M et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 5:164–170CrossRefPubMed Bex A, Mulders P, Jewett M et al (2019) Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 5:164–170CrossRefPubMed
5.
go back to reference Méjean A, Ravaud A, Thezenas S et al (2021) Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 80:417–424CrossRefPubMed Méjean A, Ravaud A, Thezenas S et al (2021) Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 80:417–424CrossRefPubMed
6.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed
7.
go back to reference Lee CH, Voss MH, Carlo MI et al (2022) Phase II trial of cabozantinib plus Nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 40:2333–2341CrossRefPubMedPubMedCentral Lee CH, Voss MH, Carlo MI et al (2022) Phase II trial of cabozantinib plus Nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 40:2333–2341CrossRefPubMedPubMedCentral
8.
go back to reference Albiges L, Gurney H, Atduev V et al (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 24:881–891CrossRefPubMed Albiges L, Gurney H, Atduev V et al (2023) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 24:881–891CrossRefPubMed
9.
go back to reference Tykodi SS, Gordan LN, Alter RS et al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 10:e003844CrossRefPubMedPubMedCentral Tykodi SS, Gordan LN, Alter RS et al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 10:e003844CrossRefPubMedPubMedCentral
10.
go back to reference Albiges L, Tannir NM, Burotto M et al (2022) First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol 81:266–271CrossRefPubMed Albiges L, Tannir NM, Burotto M et al (2022) First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial. Eur Urol 81:266–271CrossRefPubMed
11.
go back to reference Motzer RJ, Powles T, Burotto M et al (2022) Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 23:888–898CrossRefPubMedPubMedCentral Motzer RJ, Powles T, Burotto M et al (2022) Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 23:888–898CrossRefPubMedPubMedCentral
12.
go back to reference Grünwald V, Powles T, Kopyltsov E et al (2021) Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. J Clin Oncol 39:4560CrossRef Grünwald V, Powles T, Kopyltsov E et al (2021) Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. J Clin Oncol 39:4560CrossRef
13.
go back to reference Pieretti AC, Shapiro DD, Westerman ME et al (2021) Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39:837.e9-837.e17CrossRefPubMed Pieretti AC, Shapiro DD, Westerman ME et al (2021) Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urol Oncol 39:837.e9-837.e17CrossRefPubMed
14.
go back to reference Escudier B, Michaelson MD, Motzer RJ et al (2014) Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 110:2821–2828CrossRefPubMedPubMedCentral Escudier B, Michaelson MD, Motzer RJ et al (2014) Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 110:2821–2828CrossRefPubMedPubMedCentral
15.
go back to reference Iacovelli R, Lanoy E, Albiges L et al (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110:1747–1753CrossRefPubMed Iacovelli R, Lanoy E, Albiges L et al (2012) Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 110:1747–1753CrossRefPubMed
16.
go back to reference Hirsch L, Flippot R, Escudier B et al (2020) Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs 80:1169–1181CrossRefPubMed Hirsch L, Flippot R, Escudier B et al (2020) Immunomodulatory roles of VEGF pathway inhibitors in renal cell carcinoma. Drugs 80:1169–1181CrossRefPubMed
17.
go back to reference Ueda K, Suekane S, Kurose H et al (2018) Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol 36:499.e9-499.e16CrossRefPubMed Ueda K, Suekane S, Kurose H et al (2018) Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. Urol Oncol 36:499.e9-499.e16CrossRefPubMed
18.
go back to reference Hara T, Miyake H, Fujisawa M (2017) Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urol Oncol 35:363–369CrossRefPubMed Hara T, Miyake H, Fujisawa M (2017) Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urol Oncol 35:363–369CrossRefPubMed
19.
go back to reference Ueda K, Ogasawara N, Ito N et al (2023) Prognostic value of absolute lymphocyte count in patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab. J Clin Med 12:2417CrossRefPubMedPubMedCentral Ueda K, Ogasawara N, Ito N et al (2023) Prognostic value of absolute lymphocyte count in patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab. J Clin Med 12:2417CrossRefPubMedPubMedCentral
20.
go back to reference Motzer RJ, Rini BI, McDermott DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20:1370–1385CrossRefPubMedPubMedCentral Motzer RJ, Rini BI, McDermott DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20:1370–1385CrossRefPubMedPubMedCentral
21.
go back to reference Ishihara H, Kondo T, Nakamura K et al (2021) Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Jpn J Clin Oncol 51:1751–1756CrossRefPubMed Ishihara H, Kondo T, Nakamura K et al (2021) Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. Jpn J Clin Oncol 51:1751–1756CrossRefPubMed
22.
go back to reference Grünwald V, Motzer RJ, Haanen JBAG et al (2024) Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial. J Clin Oncol 42:364CrossRef Grünwald V, Motzer RJ, Haanen JBAG et al (2024) Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial. J Clin Oncol 42:364CrossRef
23.
go back to reference Haaker L, Baldewijns M, De Wever L et al (2023) Pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with nivolumab: a retrospective analysis. Clin Genitourin Cancer 21:442–451CrossRefPubMed Haaker L, Baldewijns M, De Wever L et al (2023) Pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with nivolumab: a retrospective analysis. Clin Genitourin Cancer 21:442–451CrossRefPubMed
24.
go back to reference Numakura K, Sekine Y, Hatakeyama S et al (2023) Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Med 12:16837–16845CrossRefPubMedPubMedCentral Numakura K, Sekine Y, Hatakeyama S et al (2023) Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma. Cancer Med 12:16837–16845CrossRefPubMedPubMedCentral
25.
go back to reference Yamashita S, Hamamoto S, Furukawa J et al (2024) Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol 54:722–729CrossRefPubMed Yamashita S, Hamamoto S, Furukawa J et al (2024) Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol 54:722–729CrossRefPubMed
26.
go back to reference McManus HD, Zhang D, Schwartz FR et al (2023) Relationship between pretreatment body composition and clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line ipilimumab plus nivolumab. Clin Genitourin Cancer 21:e429-e437.e2CrossRefPubMed McManus HD, Zhang D, Schwartz FR et al (2023) Relationship between pretreatment body composition and clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line ipilimumab plus nivolumab. Clin Genitourin Cancer 21:e429-e437.e2CrossRefPubMed
28.
go back to reference Tannir NM, Albigès L, McDermott DF et al (2024) Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 35:1026–1038CrossRefPubMed Tannir NM, Albigès L, McDermott DF et al (2024) Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 35:1026–1038CrossRefPubMed
Metadata
Title
Therapeutic efficacy of immune-oncology combination therapy in advanced renal cell carcinoma without prior nephrectomy
Authors
Kosuke Ueda
Naoki Ito
Yuya Sakai
Satoshi Ohnishi
Taishi Hirano
Hirofumi Kurose
Katsuaki Chikui
Keiichiro Uemura
Kiyoaki Nishihara
Makoto Nakiri
Shigetaka Suekane
Tsukasa Igawa
Publication date
03-02-2025
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-025-02710-8

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now